立方制药：全资子公司取得洛索洛芬钠口服溶液药品注册证书

Core Viewpoint - The announcement indicates that Chengzhi Biologics, a wholly-owned subsidiary of Lianfang Pharmaceutical, has received the drug registration certificate for Loxoprofen Sodium Oral Solution from the National Medical Products Administration, marking a significant milestone for the company in expanding its product pipeline [1] Group 1 - Loxoprofen Sodium is a non-steroidal anti-inflammatory drug (NSAID) with effective analgesic, anti-inflammatory, and antipyretic properties [1] - As of the announcement date, there are no imported products approved for sale in the domestic market, making Chengzhi Biologics the eighth company in China to hold the drug registration for this product [1] - The acquisition of this certificate will enhance Lianfang Pharmaceutical's product lineup and improve its market competitiveness [1] Group 2 - The production and sales of the drug will still be influenced by policies and market factors, indicating potential uncertainties in its commercialization [1]